Mar 28, 2016 4:01 pm EDT CymaBay Announces the Appointment of Paul F. Truex and Robert J. Weiland to its Board of Directors
Mar 28, 2016 8:00 am EDT CymaBay Therapeutics Announces Acceptance of Arhalofenate Phase 2b Gout Study Manuscript in Arthritis and Rheumatology
Mar 22, 2016 8:00 am EDT CymaBay Announces the Appointment of Dr. Evan Stein, M.D., Ph.D., to its Board of Directors
Mar 21, 2016 8:00 am EDT CymaBay to Announce Fourth Quarter and Year-End 2015 Financial Results on Tuesday, March 29
Mar 17, 2016 4:01 pm EDT CymaBay Therapeutics Announces Positive Results from its Pilot Phase 2 Clinical Study of MBX-8025 in Patients with Homozygous Familial Hypercholesterolemia
Mar 03, 2016 8:00 am EST CymaBay Therapeutics to Present at Two Upcoming Investor Conferences in March
Jan 20, 2016 8:00 am EST CymaBay Therapeutics Announces Successful Completion of End-of-Phase 2 Discussions With FDA for Arhalofenate